LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

Search

Rhythm Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

98.56 2.69

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

95.64

Max

98.84

Belangrijke statistieken

By Trading Economics

Inkomsten

2.9M

-47M

Verkoop

16M

49M

Winstmarge

-96.144

Werknemers

283

EBITDA

6.9M

-40M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+17.34% upside

Dividenden

By Dow Jones

Volgende Winsten

4 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

423M

6.4B

Vorige openingsprijs

95.87

Vorige sluitingsprijs

98.56

Nieuwssentiment

By Acuity

14%

86%

10 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Rhythm Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 sep 2025, 23:56 UTC

Populaire aandelen

Stocks to Watch: FedEx, 22nd Century, Scholastic

18 sep 2025, 22:01 UTC

Belangrijke Marktbewegers

22nd Century Group Shares Gain on Debt Repayment, New Capital

18 sep 2025, 20:51 UTC

Acquisities, Fusies, Overnames

UPS Terminates Plan to Buy Estafeta

18 sep 2025, 20:31 UTC

Winsten

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping -- Update

18 sep 2025, 20:26 UTC

Winsten

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping

18 sep 2025, 23:43 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

18 sep 2025, 23:43 UTC

Marktinformatie

Nikkei May Rise on U.S. Stock Gains, Weaker Yen -- Market Talk

18 sep 2025, 23:43 UTC

Marktinformatie

Global Equities Roundup: Market Talk

18 sep 2025, 23:40 UTC

Marktinformatie

Gold Edges Lower Amid Cautious Mood -- Market Talk

18 sep 2025, 23:31 UTC

Marktinformatie

FedEx Says U.S. Demand Is Resilient -- Market Talk

18 sep 2025, 22:03 UTC

Winsten

FedEx Expects Trade Environment to Create $1B Headwind in 2026, CFO Says

18 sep 2025, 22:01 UTC

Winsten

FedEx CFO: Asia-to-U.S. Declines Drove $150M International Export Headwind

18 sep 2025, 21:56 UTC

Winsten

Lennar Missed Revenue Estimates. The Stock Is Down. -- Barrons.com

18 sep 2025, 21:54 UTC

Winsten

FedEx Focused on Demand From Southeast Asia, Europe Amid China Shipping Slowdown, Customer Chief Says

18 sep 2025, 21:48 UTC

Winsten

FedEx International Export Volumes Declined, Especially on China-to-U.S. Lane, Exec Says

18 sep 2025, 21:47 UTC

Winsten

FedEx Had 5% Increase in U.S. Domestic Average Daily Package Volume in 1Q, Customer Chief Says

18 sep 2025, 21:17 UTC

Winsten

FedEx Profit, Sales Rise on Improvement in U.S. Shipping -- 2nd Update

18 sep 2025, 21:07 UTC

Winsten

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18 sep 2025, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

18 sep 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

18 sep 2025, 20:50 UTC

Marktinformatie
Winsten

Financial Services Roundup: Market Talk

18 sep 2025, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

18 sep 2025, 20:22 UTC

Acquisities, Fusies, Overnames

UPS Cites Inability of All Closing Conditions to Be Satisfied

18 sep 2025, 20:22 UTC

Acquisities, Fusies, Overnames

United Parcel Service Terminates Plan to Buy Estafeta

18 sep 2025, 20:20 UTC

Acquisities, Fusies, Overnames

Here's How Much the U.S. Has Made on Its Intel Stock Purchase -- Barrons.com

18 sep 2025, 20:18 UTC

Winsten

Nucor Stock Falls After Earnings. Why Its Guidance Was Far Off Rival Steel Dynamics. -- Barrons.com

18 sep 2025, 20:18 UTC

Winsten

Bullish Crushes Earnings. The Crypto Stock Pops. -- Barrons.com

18 sep 2025, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

18 sep 2025, 20:07 UTC

Winsten

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18 sep 2025, 20:03 UTC

Winsten

FedEx 1Q FedEx Freight Segment Revenue $2.26B >FDX

Peer Vergelijking

Prijswijziging

Rhythm Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

17.34% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 112.08 USD  17.34%

Hoogste 135 USD

Laagste 95 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Rhythm Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

13 ratings

13

Buy

0

Hold

0

Sell

Technische score

By Trading Central

60 / 65.58Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

10 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
help-icon Live chat